title: Experience with liposomal Amphotericin-B in 60 patients undergoing high-dose therapy and bone marrow or peripheral blood stem cell transplantation.
abstract: 60 patients undergoing bone marrow or stem cell transplantation were treated with liposomal Amphotericin-B for documented or suspected mycosis. 34 patients had a prior course of conventional Amphotericin-B with the following adverse effects: increasing creatinine above 1.4 mg/dl (n = 17), increasing creatinine below 1.5 mg/dl (n = 9), no response (n = 6), and clinical side-effects (n = 4). Liposomal Amphotericin-B failed in 6/7 patients with culture-proven mycosis who died from infection with Aspergillus (n = 2) and Candida (n = 4), respectively. One patient with Candida lambica sepsis was cured. No patient with clinically or serologically suspected or diagnosed infection died from mycosis. Liposomal Amphotericin-B was well tolerated in 57 patients, even after side-effects of the conventional formulation. Adverse effects occurred in three cases, requiring the withdrawal of the drug in one patient. Due to toxic side-effects of the high-dose therapy and transplant-related complications, it was difficult to evaluate the influence of liposomal Amphotericin-B on laboratory parameters. Eight patients showed a decrease of creatinine levels, which had increased above normal values under preceding therapy with conventional Amphotericin-B. Liposomal Amphotericin-B is well tolerated in patients undergoing high-dose therapy and bone marrow transplantation. The efficacy of liposomal Amphotericin-B needs to be investigated in randomized studies in comparison with conventional Amphotericin-B.
authors.affiliation: Department of Oncology/Haematology, University Hospital Eppendorf, Hamburg, Germany.
authors.forename: W
authors.initials: W
authors.lastname: Krüger
authors.forename: M
authors.initials: M
authors.lastname: Stockschläder
authors.forename: B
authors.initials: B
authors.lastname: Rüssmann
authors.forename: C
authors.initials: C
authors.lastname: Berger
authors.forename: M
authors.initials: M
authors.lastname: Hoffknecht
authors.forename: I
authors.initials: I
authors.lastname: Sobottka
authors.forename: B
authors.initials: B
authors.lastname: Kohlschütter
authors.forename: G
authors.initials: G
authors.lastname: Kroschke
authors.forename: N
authors.initials: N
authors.lastname: Kröger
authors.forename: M
authors.initials: M
authors.lastname: Horstmann
mesh_terms: D000293:Adolescent; D000328:Adult; D000666:Amphotericin B / Q000009:adverse effects / Q000627:therapeutic use*; D000935:Antifungal Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001228:Aspergillosis / Q000150:complications / Q000188:drug therapy; D016026:Bone Marrow Transplantation; D002648:Child; D002675:Child, Preschool; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006801:Humans; D007223:Infant; D008172:Lung Diseases, Fungal / Q000150:complications / Q000188:drug therapy; D008297:Male; D008875:Middle Aged; D009181:Mycoses / Q000150:complications / Q000188:drug therapy; D009503:Neutropenia / Q000150:complications; D009894:Opportunistic Infections / Q000150:complications; D016896:Treatment Outcome
chemical_list: D000935:Antifungal Agents; D000666:Amphotericin B